What is happening, page-3533

@Geeris, thanks for putting things back into perspective.

I acknowledge that my recent tone could be interpreted as spiteful towards the government-backed position of psiQ. I was merely echoing the sentiment expressed on Pitt Street's Research, which seems to indicate that a lot of AXE investors hold the incorrect belief that Archer will fall behind because of their larger cash position. But as you correctly point out, AXE is quite different and has positioned itself for a different market use. 12CQ's applications and use cases are designed to enhance or value-add current technologies, especially in reducing time and power usage, which results in the delivery of more compact mobile solutions. Thus, AXE has the potential to be directly useful to the commercial market which is yet to be realised.

Even if the current share price is a progress-lagging indicator, AXE has the potential for mass commercialisation and mass-royalities that psiQ may not, which is why government intervention is necessary. So, for AXE to obtain a re-rate, we only need to achieve a few milestones and industry validation—and that's only on the 12CQ. A double re-rate is likely when bio-chip technology news is included, or when investors start to add up the true value of what it means to be on the global stage as a mass production player.

We are certainly better positioned at the forefront of high-impact areas. It's just a matter of time.

AIMO, DYOR GLTA(patient)H